)
Visual
test
Allogene Therapeutics
Allogene Therapeutics (ALLO) investor relations material
Allogene Therapeutics Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary2 Dec, 2025
Strategic focus and clinical program updates
Allogeneic cell therapy aims to democratize treatment by reducing costs and expanding access to community cancer centers.
Lead CD19-directed CAR-T program, Cema-cel, is being evaluated in the Alpha3 study for large B-cell lymphoma as a consolidation therapy post-R-CHOP.
Alpha3 study uses MRD testing post-R-CHOP to identify high-risk patients for randomization to Cema-cel or observation.
Interim analysis of Alpha3, focusing on MRD conversion rates, is expected in the first half of next year; primary event-free survival data will follow.
Approximately half of trial sites are community-based, with most patients treated in outpatient settings.
Clinical trial design and expectations
MRD conversion is considered a strong predictor of event-free survival; a 30% difference is seen as clinically meaningful.
About one-fifth of patients are estimated to be MRD positive after frontline treatment, aligning with enrollment projections.
MRD testing is performed within one to three months post-R-CHOP, consistent with published standards.
Adoption of MRD testing is increasing in both hematology and solid tumors, supporting broader clinical use.
The Alpha3 study is designed to improve cure rates, not just event-free survival, in large B-cell lymphoma.
Autoimmune program and pipeline development
ALLO-329 is a dual CAR-T targeting CD19 and CD70, designed to address both B-cell and T-cell driven autoimmune diseases.
Phase I basket study is enrolling patients with lupus, myositis, and scleroderma, using two parallel cohorts with different lymphodepletion strategies.
Initial data in the first half of next year will focus on CAR-T expansion, biomarker changes, and early clinical responses.
CD70 targeting may enable longer remissions and expansion into T-cell driven autoimmune indications such as type 1 diabetes and multiple sclerosis.
Further development decisions on dose and lymphodepletion will require more patient data.
How does outpatient dosing impact Alpha-3 trial?
What T-cell driven diseases could ALLO-329 target?
What is the COGS advantage of allogeneic CAR-T?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebISCTR
Net profit hit TL 67.4 billion in 2025, with strong NIM, fee growth, and solid 2026 outlook. - 6 FebSCW
73% revenue growth and record backlog driven by new space contracts and strategic investments. - 6 FebCDP
2025 FFO/share rose 5.8% with strong leasing and retention; 2026 guidance signals further growth. - 6 FebSCWRevenue at 15.86 mln PLN, backlog 17.14 mln PLN, and major space contracts drive 2025 outlook.
- 6 FebPENG
All proposals passed, with no questions raised during the Q&A session. - 6 FebSCWQ2 2024 revenue up 115% y/y, backlog nearly doubled, Space segment leads growth.
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and strong acquisitions. - 6 FebSCWQ2 2025 revenue surged 120% y/y, driven by a record Asian contract and a tripled backlog.
- 6 FebSCWQ1 2025 revenue jumped 97% year-over-year, with strong backlog and major new contracts secured.
- 6 FebSCWQ3 revenue up 39% y/y, backlog at 58.3 mln PLN, Space leads growth with global contracts.
Next Allogene Therapeutics earnings date
Citi’s 2026 Virtual Oncology Leadership Summit18 Feb, 2026
Allogene Therapeutics
Next Allogene Therapeutics earnings date
Citi’s 2026 Virtual Oncology Leadership Summit18 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Allogene Therapeutics Inc is a biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment. The company’s approach uses gene-editing and cell engineering technologies to produce off-the-shelf immunotherapies designed to target various hematologic and solid tumors. Its operations span research, clinical trials, and manufacturing. Allogene Therapeutics Inc is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage